NASDAQ$AXSM
Axsome Therapeutics Inc · Q2 2020 earnings
Q2 2020 earnings · · Investor relations
Briefing
Axsome reported financial results for the second quarter ended June 30, 2020 and provided a business update.
Axsome Therapeutics reported its Q2 2020 financial results, highlighting progress in its CNS pipeline with multiple FDA Breakthrough Therapy designations and advancements towards NDA submissions for AXS-05 and AXS-07. The company is on track with clinical trials and anticipates key milestones in the near term.
- Two NDA submissions for AXS-05 in MDD and AXS-07 in migraine are on track for Q4 2020.
- Enrollment was completed for Phase 3 long-term safety trials of AXS-05 in MDD and AXS-07 in migraine.
- Results from three Phase 2 open-label efficacy trials of AXS-05 in TRD, antidepressant unresponsive MDD, and suicidal ideation are expected in Q4 2020.
- Phase 3 trials for AXS-05 in Alzheimer’s disease agitation and AXS-12 in narcolepsy are on track for Q4 2020.
Headline financials
Revenue & EPS history
Axsome · Revenue · Quarterly
$191M
Revenue by segment
Axsome · $57.8M total across 2 segments · Q3 2023
- AUVELITY$37.7M—65.2%
- SUNOSI$20.1M+19.6%34.8%
Forward guidance
Axsome believes that its cash at June 30, 2020 will be sufficient to fund the Company’s anticipated operations, based on its current operating plans, for at least two years.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2020
-1.0%
Avg return
Earnings day
-2.9%
Avg return
5 days after
+1.7%
Avg return
30 days after
51%
21 / 41 earnings
Positive
+12.9%
Q1 2022
Best reaction
-53.5%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +8.1% | +5.3% | +13.0% | |
| Q4 2025 | -4.7% | -10.8% | -11.9% | |
| Q3 2025 | +1.9% | +2.3% | +9.5% | |
| Q1 2025 | +3.7% | -4.0% | -3.6% | |
| Q4 2024 | -2.3% | +5.0% | -3.7% | |
| Q3 2024 | +7.5% | +2.4% | +3.7% | |
| Q2 2024 | +1.3% | -1.6% | +13.2% | |
| Q1 2024 | +2.9% | -3.1% | -0.9% | |
| Q4 2023 | -11.5% | -14.9% | -12.9% | |
| Q3 2023 | -3.1% | -11.9% | +6.5% | |
| Q2 2023 | -1.5% | -5.5% | +10.7% | |
| Q1 2023 | +4.1% | +7.1% | +2.4% | |
| Q4 2022 | +11.7% | +6.9% | +2.3% | |
| Q3 2022 | +11.2% | +3.4% | +36.9% | |
| Q2 2022 | +11.7% | +6.8% | +41.3% | |
| Q1 2022 | +12.9% | -6.1% | -24.3% | |
| Q4 2021 | +11.9% | +6.4% | +47.2% | |
| Q3 2021 | +1.4% | -2.3% | -12.6% | |
| Q2 2021 | -53.5% | -55.3% | -48.9% | |
| Q1 2021 | +0.1% | +2.6% | +11.5% | |
| Q4 2020 | +3.6% | -3.5% | -15.9% | |
| Q3 2020 | -9.7% | -6.3% | +7.1% | |
| Q2 2020 | -0.6% | +1.2% | -7.3% | |
| Q1 2020 | -2.8% | -7.9% | -15.7% | |
| Q4 2019 | -16.8% | -38.7% | -23.8% | |
| Q3 2019 | -1.2% | -4.6% | +76.4% | |
| Q2 2019 | +2.2% | +11.0% | -0.5% | |
| Q1 2019 | +7.2% | +10.7% | +12.2% | |
| Q4 2018 | +4.6% | +24.3% | +29.2% | |
| Q3 2018 | -15.8% | -28.1% | -24.7% | |
| Q2 2018 | -1.9% | -8.6% | +27.6% | |
| Q1 2018 | +1.5% | +3.0% | +4.5% | |
| Q4 2017 | +2.6% | +6.5% | -8.4% | |
| Q3 2017 | -4.1% | +1.0% | -0.5% | |
| Q2 2017 | -5.0% | -12.6% | -19.3% | |
| Q1 2017 | -1.2% | -1.2% | -4.8% | |
| Q4 2016 | -4.1% | +6.1% | -27.6% | |
| Q3 2016 | +0.7% | +4.1% | -17.8% | |
| Q2 2016 | -1.4% | -3.4% | -1.6% | |
| Q1 2016 | -1.4% | -3.4% | -1.6% | |
| Q4 2015 | -10.0% | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro